May 23, 2022
If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery time. The Evaluate Vantage team has produced its round up of the investment and financial side of the industry and the results make for interesting – if sobering – reading.
Register now to receive your copy.
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
September 5, 2024
Solid proof now exists that pharmacological intervention can help shift excess body weight. Yet, many questions remain, including: What’s the potential market size? How much is the pipeline worth? Which ...
August 19, 2024
Navigating the complex landscape of rare diseases requires a specialized approach. With over 7,000 types of rare diseases affecting more than 300 million people globally, and only a fraction having ...
August 12, 2024
Going into 2024, hopes were moderately high for dealmaking and the wider financial landscape in pharma. M&A and IPOs were picking up, offering investors the exit opportunities they need. But ...
Do the pharmaceutical industry’s billion-dollar drugs have an X-factor? To better understand the blockbuster landscape and identify the key characteristics driving their success, we’ve analysed Evaluate Pharma data on nearly ...
July 9, 2024
Last year’s Age of Uncertainty has given way to more predictable realities. Obesity drugs are set to dominate the 2030 forecasts, with more potent compounds, combinations, and oral formulations likely ...
After an Age of Uncertainty, the pharmaceutical industry is now shifting into a period with more predictable trends, where big pharma continues to focus on big drugs for big diseases. ...
